C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases.

C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases.
复制标题

C反应蛋白与白蛋白比值是初诊慢性淋巴细胞白血病独立不良预后因素:322例临床分析

DOI:
10.1016/j.tranon.2021.101035
复制
发表时间:
2021-04
影响因子:
5
通讯作者:
Li JY
Li JY
中科院分区:
医学3区
文献类型:
--
作者:
Tang HN;Pan BH;Wang L;Zhu HY;Fan L;Xu W;Li JY

文献摘要

参考文献

被引文献

相似文献

第一项研究集中在血清C-反应蛋白与白蛋白(CRP/ALB)比值作为慢性淋巴细胞白血病(CLL)的癌症相关全身炎症和营养不良参数。第一项研究显示,诊断前CRP/ALB比值(CAR)与不利的无治疗生存期(TFS)和总生存期(OS)相关。CAR仅是OS的独立预后指标,而不是TFS。增加高CAR标准可提高CLL-IPI预测OS的能力,尤其是对中危组和高危组的预测能力。CAR可能是预测预后和评估抗炎和营养改善治疗的有效性在未来的临床实践中的CLL的良好候选人。慢性淋巴细胞白血病是成人白血病中最常见的类型之一。癌症相关的全身炎症反应已被表征为与癌症患者的治疗结果相关。C反应蛋白与白蛋白(CRP/ALB)比值(CAR)是一种炎症标志物,已被报道为几种癌症的新预后因子。我们研究的目的是评估CAR在慢性淋巴细胞白血病(CLL)患者中的预后价值。我们回顾性分析了322例新诊断的CLL患者的临床特征,研究了治疗前CAR、无治疗生存期(TFS)和总生存期(OS)之间的相关性,通过曲线下面积(AUC)评估CAR与其他炎症相关预后指标的预后作用,并将CAR和CLL-IPI结合在一起,以改进现有的预后系统。结果表明,CAR是一个独立的OS预后因素,联合检测CLL-IPI对OS的预测和鉴别能力上级单独检测CLL-IPI。结论:血清CRP和ALB水平是一个简单易行的指标,其比值CAR可作为预测CLL预后的良好指标。
The first study to concentrate on serum C-reactive protein-to-albumin (CRP/ALB) ratio as an cancer-associated systemic inflammation and malnutrition parameter in chronic lymphocytic leukemia (CLL). The first study showing pre-diagnostic CRP/ALB ratio (CAR) was associated with unfavorable treatment-free survival (TFS) and overall survival (OS). CAR was an independent prognostic indicator only for OS, not for TFS. Adding the criterion of high CAR could improve the prognostic capacity of CLL-international prognostic index (CLL-IPI) in OS prediction, especially in intermediate risk group and high risk group. CAR may be good candidates for predicting prognosis and evaluating effectiveness of anti-inflammatory and nutrition improvement treatments in the future clinical practice of CLL. Chronic lymphocytic leukaemia is one of the most common types of adult leukaemia. Cancer-related systemic inflammation response has been characterized to correlate with therapeutic outcome in patients with cancer. The C-reactive protein-to-albumin (CRP/ALB) ratio (CAR), which is an inflammatory marker, has been reported as a novel prognostic factor in several cancers. The aim of our study was to evaluate the prognostic value of the CAR in patients with chronic lymphocytic leukaemia (CLL). We retrospectively reviewed the clinical characteristics of 322 newly diagnosed CLL patients, investigated the correlations among pretreatment CAR, treatment-free survival (TFS) and overall survival (OS), assessed the prognostic effect of the CAR to compare with other inflammation-related prognostic index by the area under the curve (AUC), and combined CAR and CLL-international prognostic index (CLL-IPI) together to improve the current prognostic system. The results showed that CAR was an independent prognostic factor for OS. Furthermore, the predictive and discriminatory capacity of CLL-IPI together with CAR level was superior to that of CLL-IPI alone for OS. In conclusion, serum CRP and ALB levels are both simple and easily accessible parameters, whose ratio CAR may be good candidates for predicting prognosis in the future clinical practice of CLL.
DOI: 10.3305/nh.2014.29.3.7195
发表时间: 2014-03-01
期刊: Nutrición Hospitalaria
影响因子: --
作者:
Alberici Pastore, Carla;Paiva Orlandi, Silvana;Gonzalez, Maria Cristina
通讯作者: Gonzalez, Maria Cristina
DOI: 10.1007/s00268-016-3491-4
发表时间: 2016-09-01
影响因子: 2.6
作者:
Haruki, Koichiro;Shiba, Hiroaki;Yanaga, Katsuhiko
通讯作者: Yanaga, Katsuhiko
DOI: 10.1245/s10434-014-4048-0
发表时间: 2015-03-01
影响因子: 3.7
作者:
Kinoshita, Akiyoshi;Onoda, Hiroshi;Matsushima, Masato
通讯作者: Matsushima, Masato
DOI: 10.1016/j.clnu.2015.04.013
发表时间: 2016-04-01
期刊: CLINICAL NUTRITION
影响因子: 6.3
作者:
Mocellin, Michel C.;Camargo, Carolina Q.;Trindade, Erasmo B. S. M.
通讯作者: Trindade, Erasmo B. S. M.
DOI: 10.1097/md.0000000000000481
发表时间: 2015-02
期刊: Medicine
影响因子: 1.6
作者:
Liu YL;Lu Q;Liang JW;Xia Y;Zhang W;Hu BQ;Shang FF;Ji YR;Wang J;Wang Q;Liang B
通讯作者: Liang B